Volume 35, Issue 1, March 2024

Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2023;34(4):513-24
Long Term Outcomes in Idiopathic Inflammatory Myositis: An Observational Epidemiologic Study over 15 Years
Authors Information

1Department of Clinical Immunology and Rheumatology, St. John's Medical College Hospital, Bengaluru, Karnataka, India

2Department of Biostatistics, St. John's Medical College Hospital, Bengaluru, Karnataka, India

3Department of Neurology, St. John's Medical College Hospital, Bengaluru, Karnataka, India

4Department of Pathology, NIMHANS, Bengaluru, Karnataka, India

  1. Schmidt J. Current Classification and Management of Inflammatory Myopathies. J Neuromuscul Dis 2018;5:109-29.
  2. Rider LG, Aggarwal R, MacHado PM, Hogrel JY, Reed AM, Christopher-Stine L, et al. Update on outcome assessment in myositis. Nat Rev Rheumatol 2018;14:303-18.
  3. Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, et al. International Myositis Outcome Assessment Collaborative Study Group. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 2001;40:1262-73. 
  4. Shu XM, Lu X, Xie Y, Wang GC. Clinical characteristics and favorable long-term outcomes for patients with idiopathic inflammatory myopathies: A retrospective single center study in China. BMC Neurol 2011;11:1–11.
  5. Lilleker JB, Vencovsky J, Wang G, Wedderburn L, Pyndt Diederichsen L, Schmidt J, et al. The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis 2018;77:30–9.
  6. Gupta L, Appani SK, Janardana R, Muhammed H, Lawrence A, Amin S, et al. Meeting report: MyoIN-Pan-India collaborative network for myositis research. Indian J Rheumatol 2019;14:136–42.
  7. Rider LG, Dankó K, Miller FW. Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research. Curr Opin Rheumatol 2014;26:724-41.
  8. Aguilar-Vazquez A, Chavarria-Avila E, Pizano-Martinez O, Ramos-Hernandez A, Andrade-Ortega L, Rubio-Arellano ED, et al. Geographical Latitude Remains as an Important Factor for the Prevalence of Some Myositis Autoantibodies: A Systematic Review. Front Immunol 2021;12:672008.
  9. Muhammed H, Gupta L, Zanwar AA, Misra DP, Lawrence A, Agarwal V, et al. Infections Are Leading Cause of In-Hospital Mortality in Indian Patients With Inflammatory Myopathy. J Clin Rheumatol 2021;27:114-9.
  10. Porkodi R, Shanmuganandan K, Parthiban M, Madhavan R, Rajendran P. Clinical spectrum of inflammatory myositis in South India - A ten year study. J Assoc Physicians India 2002;50:1255-8.
  11. Mehta P, Agarwal V, Gupta L. High early mortality in idiopathic inflammatory myopathies: results from the inception cohort at a tertiary care centre in northern India. Rheumatology (Oxford) 2021;60(9):4281-90.
  12. Rajasekhar L, Shobha V, Narasimhan A, Bhat V, Amin SN, Misra R. Prevalence and Clinical Correlates of Myositis Specific Autoantibodies in Idiopathic Immune-Mediated Inflammatory Myositis - Results from a Multicentric Cohort (MyoIN) from India. J Assoc Physicians India 2021;69(1):36-40.
  13. Pinto, B., Janardana, R., Nadig, R.  et al. Comparison of the 2017 EULAR/ACR criteria with Bohan and Peter criteria for the classification of idiopathic inflammatory myopathies. Clin Rheumatol 2019;38:1931-4.
  14. Nair AM, Mathew J, Goel R, Chebbi P, Mathew AJ, Arvind G et al. Mycophenolate in idiopathic inflammatory myositis: outcome data of a large South Asian cohort. Clin Rheumatol 2021;40:2805-19.
  15. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
  16. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.
  17. Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, et al. 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis Rheumatol 2017;69:2271-82.
  18. Allenbach Y, Mammen AL, Benveniste O, Stenzel W, Allenbach Y, Amato A, et al. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14–16 October 2016. Neuromuscul Disord 2018;28:87-99.
  19. Senécal JL, Raynauld JP, Troyanov Y. Editorial: A New Classification of Adult Autoimmune Myositis. Arthritis Rheumatol 2017;69:878-84.
  20. Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senécal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: Analysis of 100 French Canadian patients. Medicine (Baltimore) 2005;84:231-49.
  21. Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): A missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 2006;54:597-613.
  22. Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis. Arthritis Care Res 2011;63(SUPPL. 11). S118-57.
  23. Oddis C V., Rider LG, Reed AM, Ruperto N, Brunner HI, Koneru B, et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 2005;52:2607-15.
  24. Neri R, Mosca M, Stampacchia G, Vesprini E, Tavoni A, D’Ascanio A, et al. Functional and isokinetic assessment of muscle strength in patients with idiopathic inflammatory myopathies. Autoimmunity 2006;39:255-9.
  25. Bronner IM, Van Der Meulen MFG, De Visser M, Kalmijn S, Van Venrooij WJ, Voskuyl AE, et al. Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis. 2006;65:1456-61.
  26. D. A. Isenberg, E. Allen, V. Farewell, M. R. Ehrenstein, M. G. Hanna, I. E. Lundberg, et.al., for the International Myositis and Clinical Studies Group (IMACS), International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology 2004;43(1):49-54.
  27. Chinniah KJ, Mody GM. The spectrum of idiopathic inflammatory myopathies in South Africa. Clin Rheumatol 2021;40:1437-46.
  28. Mariampillai K, Granger B, Amelin D, Guiguet M, Hachulla E, Maurier F, et al. Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies. JAMA Neurol 2018;75:1528-37.
  29. Ramesha KN, Kuruvilla A, Sarma PS, Radhakrishnan VV. Clinical, electrophysiologic, and histopathologic profile, and outcome in idiopathic inflammatory myositis: An analysis of 68 cases. Ann Indian Acad Neurol 2010;13:250-56.
  30. Ponyi A, Borgulya G, Constantin T, Váncsa A, Gergely L, Dankǒ K. Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis. Rheumatolog .2005;44:83-8.
  31. Murray SG, Schmajuk G, Trupin L, Lawson E, Cascino M, Barton J, et al. A population-based study of infection-related hospital mortality in patients with dermatomyositis/polymyositis. Arthritis Care Res 2015;67:673-80.
  32. Ishizuka M, Watanabe R, Ishii T, Machiyama T, Akita K, Fujita Y, et al. Long-term follow-up of 124 patients with polymyositis and dermatomyositis: Statistical analysis of prognostic factors. Mod Rheumatol 2016;26:115-20.
  33. Galindo-Feria AS, Rojas-Serrano J, Hinojosa-Azaola A. Clinical and prognostic factors associated with survival in Mexican patients with idiopathic inflammatory myopathies. J Clin Rheumatol 2016;22:51-6.
  34. Nuño-Nuño L, Joven BE, Carreira PE, Maldonado-Romero V, Larena-Grijalba C, Cubas IL, et al. Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain. Rheumatol Int 2017;37:1853-61.
  35. Dankó K, Ponyi A, Constantin T, Borgulya G, Szegedi G. Long-Term Survival of Patients with Idiopathic Inflammatory Myopathies According to Clinical Features: A Longitudinal Study of 162 Cases. Medicine (Baltimore) 2004;83:35-42.